SELENOI

Across TCGA pan-cancer cohorts, SELENOI mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SELENOI’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where SELENOI mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types SELENOI is over-expressed in tumor, although a few such as PDAC show the opposite, repressed pattern.

COAD, LSCC, and HNSC are the cancer types where SELENOI tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SELENOI mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	All	+0.466	<.001	11	view →
LSCC	Female	II,III,IV	+0.759	<.001	8	view →
HNSC	Male	All	+0.250	<.001	8	view →
PDAC	Female	All	−1.032	<.001	6	view →
LUAD	All	All	+0.295	<.001	5	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

SELENOI–COAD

Open the COAD breakdown →